MAGEA3 and metastatic malignant neoplasm: Moreover, adoptive CD4+ T cell therapy using HLA-DPB1*0401 restricted TCR recognizing MAGEA3 has been proved to be effective in 17 patients with metastatic cancer and 4/17 patients treated with DPB1*0401 restricted TCR-T cells showed durable clinical response (1CR, 3PR) (67).